A new entity of acute leukemia coexpressing CD4+ CD56+ markers without any other
lineage-specific markers has been identified recently as arising from lymphoid-related …

BACKGROUND AND OBJECTIVES: The CD4+ CD56+ lin-immunophenotype characterizes
rare malignancies, so far considered as arising from the transformation of NK progenitors …

We identified CD22 expression on a blastic plasmacytoid dendritic cell (pDC) neoplasm
presenting as a leukemia in a child. CD22 expression, as determined by the antibody s‐HCL …

OBJECTIVE: The aim of this study was to determine whether expression of the CD86
costimulatory molecule in acute myeloid leukemia (AML) can identify blast cells committed to …

CD123 has been identified as a specific surface marker for plasmacytoid dendritic cells
(PDCs). However, CD123 has recently been shown to be expressed on freshly isolated or in …

This work aims to demonstrate that CD4+ CD56+ malignancies arise from transformed cells
of the lymphoid-related plasmacytoid dendritic cell (pDC) subset. The analysis of malignant …

CD4+ CD56+ malignancies are rare hematologic neoplasms, which were recently shown to
correspond to the so-called type 2 dendritic cell (DC2) or plasmacytoid dendritic cells. This …

Recently, a population of M-DCS-positive leukocytes has been described as a new
subpopulation of human dendritic cells (DC). In view of the expression of the CD16 antigen …

Dendritic cells (DCs) play a central role in immune regulation. Some leukemic cells are
argued to be malignant counterparts of DC because of their ability to differentiate into …

CAMPATH antibodies recognize CD52, a phosphatidylinositol-linked membrane protein
expressed by mature lymphocytes and monocytes. Since some antigen-presenting dendritic …